The Top 3 Stocks to Watch in April 2019
If you really want to become a better investor then you need to be looking at where the smart money is heading. You need to understand what is truly driving the markets and how you can take advantage of these moves as – and before – they hit the mainstream.
That’s how the long-term wealth can be found.
For example, in January 2019, we noted that Fate Therapeutics (FATE) was a great opportunity at $12 a share. It’s now up to $18.41.
We also highlighted Glu Mobile (GLUU) around $7.75. It’s now up to $11.14.
Today, we’ve uncovered three stocks that have the same potential.
Small Cap Bargain No. 1—Arotech Corporation (NASDAQ:ARTX)
In early March 2019, the president said he would submit a budget to Congress that included a request for $750 billion for fiscal year 2020.
Within the budget, more than $718 billion of that would go to the Pentagon — a year-over-year increase of $34 billion. That includes $31 billion to modernize our nuclear facilities, in addition to funding for a Virginia-class submarine and 78 F-35 jets from Lockheed Martin.
The president also requested $13.6 billion to upgrade existing missile defenses and begin the development of space-based weapons to counter hypersonic missile threats. After all, Russia has a missile that can travel at nearly two miles a second or 6,138 miles an hour.
One of the many stocks that could benefit from that budget is Arotech Corporation — a defense and security products and services company. It manufactures and designs products for military and non-military air and ground vehicles; interactive simulation for military, law enforcement and commercial markets, and batteries and charging systems for the military.
Small Cap Bargain No. 2 – Nabriva Therapeutics (NASDAQ:NBRV)
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections.
At the moment, the stock is consolidating with heavy volume. As we near June 30, 2019, we believe the stock could push significantly higher. That’s when the FDA will rule on its Contepo IV drug for the treatment of complicated urinary tract infections.
Small Cap Bargain No. 3 — The Meet Group (NASDAQ:MEET)
The Meet Group, Inc. operates various mobile social entertainment applications. Its applications are designed to meet the universal need for human connection. The company leverages a powerful live-streaming video platform, empowering global community to forge meaningful connections. The company’s primary applications include, MeetMe, LOVOO, Skout, and Tagged, which keeps mobile daily active users, entertained and engaged, and originate numbers of casual chats, friendships, dates, and marriages.
While dating sites may not sound like the best investments, MEET has been in a sizable uptrend since December 2018. Analysts at Roth Capital believe the latest pullback in the stock is a buying opportunity.
“Our fundamental checks of App Annie and other services we use to track MeetMe, Lovoo and its portfolio of apps is basically unchanged,” analysts noted. “While we acknowledge the stock broke a technical moving average, we believe this material pullback creates a buying opportunity in what is a fundamentally sound story.”
The firm reiterated a Buy rating and price target of $8.00.
Again, if you really want to become a better investor then you need to be looking at where the smart money is heading. You need to understand what is truly driving the markets and how you can take advantage of these moves as – and before – they hit the mainstream.
That’s how the long-term wealth can be found. And we believe these four stocks above can offer that long-term.
This manual is for informational and entertainment purposes only. The author is not an investment adviser, financial adviser, or broker, and the material contained herein is not intended as investment advice. If you wish to obtain personalized investment advice, you should consult with a Certified Financial Planner (CFP). All statements made in this manual are based on the author’s own opinion. Neither the author or the publisher warrants or assume any responsibility for the accuracy of the statements or information contained in this manual, and specifically disclaims the accuracy of any data, including stock prices and stock performance histories. No mention of a particular security or instrument herein constitutes a recommendation to buy or sell that or any security or instrument, nor does it mean that any particular security, instrument, portfolio of securities, transaction or investment strategy is suitable for any specific individual. Neither the author or the publisher, can assess, verify, or guarantee the accuracy, adequacy, or completeness of any information, the suitability or profitability of any particular investment or methodology, or the potential value of any investment or informational source. READERS BEAR THE SOLE RESPONSIBILITY FOR THEIR OWN INVESTMENT DECISIONS. NEITHER THE AUTHOR OR THE PUBLISHER IS RESPONSIBLE FOR ANY LOSSES DUE TO INVESTMENT DECISIONS MADE BASED ON INFORMATION PROVIDED HEREIN. At the time of writing, neither the author or the publisher has a position in any of the stocks mentioned in this manual.